Professor Darius Armstrong-James
I am a clinical senior lecturer in respiratory fungal diseases at the National Heart and Lung Institute, Imperial College London and honorary consultant physician in infectious diseases and medical mycology to the Royal Brompton and Harefield NHS Trust. My research is primarily on innate immunity to Aspergillus fumigatus with a particular focus on macrophage cell biology and signal transduction. In addition I am involved in clinical translation relevant to medical mycology.
Professor Stuart Levitz
Dr. Stuart M. Levitz is a Professor of Medicine and Microbiology & Physiological Systems at the University of Massachusetts Medical School. Dr. Levitz’s over 150 research publications have mostly focused on the mechanisms by which the immune system controls fungal pathogens and the strategies that fungi utilize to circumvent host defenses. Particular areas of interest include how fungal glycosylation influences immune responses, the mechanisms by which phagocytes exert antifungal activity and fungal vaccine development. Dr. Levitz sees patients on the Transplant Infectious Diseases consultation service at UMassMemorial Hospital.
Dr Neil McCarthy
Neil completed his Ph.D. in mucosal immunology at Imperial College London before conducting post-doctoral research in inflammatory bowel disease under the guidance of Prof. Stella Knight at St. Mark’s Hospital, one of world’s first specialist centres for intestinal diseases. He subsequently moved to the laboratory of Dr. Andy Stagg at QMUL where he established an independent research programme focused on microbe-responsive γδ T-cells in mucosal immunity and inflammation. His ongoing work seeks to understand how human γδ T-cells modify conventional gut leukocyte responses to control inflammation and mediate host protection against microbial pathogens.
Mr Malcolm Qualie
MSc BSc (Hons) MGPC , FRPS, Pharmacy Lead, Specialised Commissioning, NHS England
Malcolm qualified in 1984 with BSc in Pharmaceutical Sciences and gained a Masters in Pharmaceutical Sciences in 1987. He has worked at Royal Liverpool, St James Leeds and University Hospitals of Leicester.
His current post is Pharmacy Lead of Specialised Services within NHS England having held the post of Head of Health Policy and Pharmaceutical Advisor to the East Midland Specialised Commissioning Group for the previous two years.
Malcolm is a past Committee member of the UHL Therapeutic Advisory Service and managed the East Midland-wide Clinical Priorities Advisory Group that was responsible for agreeing policy for specialised treatments for East Midlands’ patients. In addition, Malcolm is a member of the National Pharmaceutical Supply Group and Medicines Optimisation CRG, an advisor to the National IVIG Guidelines Group and a member of the NICE Commissioner reference panel for NICE Guidelines, NICE costing toolkits and the Patient Access Scheme Advisory Group.
Malcolm took up the role of Pharmacy Lead for Specialised Services within NHS England in April 2013 and became a Fellow of the Royal Pharmaceutical Society in 2016.
Dr Fiona Rudkin
Fiona Rudkin obtained her PhD in microbiology from the University of Aberdeen in 2015. Prior to this, Fiona worked in the Global Biotherapeutics Division at Pfizer on early-stage drug discovery programmes. Her PhD and subsequent work as a Research Fellow in the MRC Centre for Medical Mycology at the University of Aberdeen was focused on generating and validating human antibodies as potential new diagnostics and therapeutics for the major human fungal pathogen Candida. In 2017, Dr. Rudkin was awarded a Royal Society of Edinburgh Enterprise Fellowship to commercialize this research and create mycoBiologics – a new spin out company developing human antibodies to combat the urgent problems in diagnosing and treating serious fungal infections.
Dr Marat Stanzani
I received my medical degree from the University of Bologna in 1997 and completed training in haematology in Bologna from 1998-2002. As part of my Ph.D. dissertation, I completed a post-doctoral fellowship at the University of Texas M.D. Anderson Cancer Center in Houston where my research focused on transplant immunology and host T-cell responses to fungal infection. After returning to Bologna in 2004, my clinical responsibilities have focused on care for patients with hematological malignancies and undergoing allogeneic haematopoietic stem cell transplantation. My current research focuses on clinical risk stratification tools and strategies for improving the diagnosis of invasive fungal diseases.
Professor Christopher Thornton
I am Professor of Fungal Immunology in the Department at Biosciences at the University of Exeter, and Director of ISCA Diagnostics Ltd., a company specializing in high integrity monoclonal antibodies for tracking human pathogenic fungi. My research encompasses fungal biology and immunology, and bench-to-bedside translation of University R&D in fungal diagnostics to the medical sector. I developed the patented lateral-flow assay for diagnosis of invasive pulmonary aspergillosis (IPA), due to be released as a CE marked IVD by OLM Diagnostics. More recently, my work has focused on antibody-guided imaging of Aspergillus lung infections in vivo using Immuno-PET/MR.
Professor Paul Verwij
Paul Verweij is a Professor at the Radboud University Medical Centre and board member of the Centre of Expertise in Mycology Radboudumc/CWZ. He is also director of the national mycology reference laboratory.
Professor Verweij’s main research interest is the management of invasive fungal diseases. Topics of interest include the diagnosis of invasive mycoses by non-cultured based methods such as biological markers and fungal DNA; the emergence of azole resistance in Aspergillus, addressing the origin and epidemiology of resistance, and clinical management; and the efficacy of antifungal agents in relation to pharmacodynamic and pharmacokinetic parameters using experimental models of fungal infection.